Neoadjuvant Chemo Did Not Improve Disease-Free Survival - Summary - MDSpire
From the Journals

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches

  • By

  • Andrea Surnit

  • May 1, 2026

  • 5 min

Share

The randomized phase 3 NeoCol trial found no significant difference in disease-free survival between neoadjuvant chemotherapy and upfront surgery in patients with locally advanced colon cancer. Conducted across nine centers in Scandinavia from 2013 to 2020, the study involved 250 participants staged via computed tomography. Although neoadjuvant chemotherapy appeared feasible, pathologic downstaging was observed, and the need for adjuvant chemotherapy decreased. Further exploration into patient stratification based on biomarkers like mismatch repair status is necessary for future applications.

Original Source(s)

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

  • by Andrea Surnit

  • May 1, 2026

Related Content

Inflammation Tied to Organ Failure Risk

Review outlines mechanisms, prognosis, and supportive care strategies in surgical and trauma ICU populations

Early Enteral Feeding Tied to Fewer Complications

Benefit driven by fewer infections and pulmonary events, though overall complication rates were similar

AI in Surgery: Debate Highlights Benefits, Gaps

Surgeons and researchers clash over whether current AI systems are ready for clinical use — and what responsible adoption would require.